Investor's Business Daily: UB prof's drug begins Phase 1 human testing

Release Date: November 27, 2007

An article in Investor's Business Daily reports Kinex Pharmaceuticals LLC has begun Phase 1 human testing of its new drug, KX2-391, and quotes David Hangauer, associate professor of chemistry and cofounder of Kinex, who said, "What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model."

Media Contact Information

John DellaContrada
Interim Vice President for Communications
Tel: 716-645-4601 (mobile: 716-361-3006)
dellacon@buffalo.edu
Twitter: @UBNewsSource